4.4 Article

9p21 index as estimated by dual-color fluorescence in situ hybridization is useful to predict urothelial carcinoma recurrence in bladder washing cytology

Journal

HUMAN PATHOLOGY
Volume 40, Issue 12, Pages 1783-1789

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2009.06.011

Keywords

Bladder washing cytology; Fluorescence in situ hybridization; 9p21 index; Recurrence; Urinary bladder; Urothelial carcinoma

Categories

Ask authors/readers for more resources

Recent studies have shown that chromosome 9p21 locus is frequently deleted in the early stages of urothelial carcinogenesis. To study the predictive value of the 9p21 aberrations in recurrence of urothelial carcinoma of the urinary bladder, we applied dual-color fluorescence ill Situ hybridization for 9p21 and chromosome 9 centromere to the bladder washing cytology samples that were obtained from the patients With urothelial carcinoma of the urinary bladder treated by transurethral resection. For the evaluation, the 9p21 index was defined as the ratio of the mean number of 9p21 signals per nucleus for that of the chromosome 9 centromere signals per nucleus in each of the bladder washing cytology samples. The 9p21 index values of the bladder washing cytology samples with no (G0) cytologic atypia were significantly higher than those of the bladder washing cytology samples with moderate (G2) (P < .01) and severe (G3) (P < .001) cytologic atypia, but the index values did not statistically differ from those of the bladder washing cytology samples with mild (G1) cytologic atypia. Recurrence-free survival ill the patients with a low 9p21 index value (<0.9) was significantly poorer in comparison with the patients with a high 9p21 index value (>0.9). Furthermore, 2 patients of bladder washing cytology G1 with a low 9p21 index value recurred much sooner than the other patients of the bladder washing cytology G1 category. These findings indicate that a decreased 9p21 index value is associated with recurrence of urothelial carcinoma of the urinary bladder, and the 9p21 index may be useful as a marker to identify patients with elevated risk of recurrence of urothelial carcinoma of the urinary bladder. (C) 2009 Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Urology & Nephrology

Transperitoneal versus retroperitoneal laparoscopic adrenalectomy for large pheochromocytoma: Comparative outcomes

Koji Shiraishi, Seiji Kitahara, Hideaki Ito, Kazuo Oba, Chietaka Ohmi, Hideyasu Matsuyama

INTERNATIONAL JOURNAL OF UROLOGY (2019)

Meeting Abstract Oncology

Relation between clinicopathological findings and PD-1 or PD-L1 status in non-clear cell renal cell carcinoma by a multicenter study.

Hiroaki Matsumoto, Kazuhiro Nagao, Masahiro Samoto, Junichi Mori, Kosuke Shimizu, Ryo Inoue, Yoshiaki Yamamoto, Seiji Yano, Hiroshi Hirata, Tomoyuki Shimabukuro, Hideyasu Matsuyama

JOURNAL OF CLINICAL ONCOLOGY (2019)

Meeting Abstract Oncology

The role of adjuvant chemotherapy for pT2-4 upper urinary tract urothelial cancer: Exploratory analysis of large multi-institutional study (JCOG1110A).

Junichi Inokuchi, Kentaro Kuroiwa, Hiroyuki Nishiyama, Takahiro Kojima, Yoshiyuki Kakehi, Mikio Sugimoto, Toshiki Tanikawa, Hiroyuki Fujimoto, Momokazu Gotoh, Naoya Masumori, Osamu Ogawa, Masatoshi Eto, Chikara Ohyama, Akito Yamaguchi, Hideyasu Matsuyama, Tomohiko Ichikawa, Keiichi Ito, Junki Mizusawa, Junko Eba, Seiji Naito

JOURNAL OF CLINICAL ONCOLOGY (2019)

Article Oncology

Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma

Shuji Mikami, Ryuichi Mizuno, Tsunenori Kondo, Nobuo Shinohara, Norio Nonomura, Seiichiro Ozono, Masatoshi Eto, Katsunori Tatsugami, Tatsuya Takayama, Hideyasu Matsuyama, Takeshi Kishida, Mototsugu Oya

CANCER SCIENCE (2019)

Article Pharmacology & Pharmacy

Pharmacokinetics of Neoadjuvant Axitinib Influenced the Efficacy in Patients With Advanced Renal Cell Carcinoma

Yoshiaki Yamamoto, Toru Otori, Ryo Inoue, Seiji Yano, Hiroshi Hirata, Hiroaki Matsumoto, Kenji Matsuyama, Hideyasu Matsuyama

JOURNAL OF CLINICAL PHARMACOLOGY (2020)

Article Urology & Nephrology

Transcriptome Analysis to Identify Human Spermatogonial Cells from Sertoli Cell-Only Testes

Koji Shiraishi, Masanori Tabara, Hideyasu Matsuyama

JOURNAL OF UROLOGY (2020)

Article Oncology

Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer

Masaki Shiota, Naohiro Fujimoto, Yoshiaki Yamamoto, Ario Takeuchi, Katsunori Tatsugami, Takeshi Uchiumi, Hideyasu Matsuyama, Masatoshi Eto

CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)

Article Urology & Nephrology

The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients

Kimihiko Nakamura, Yudai Nagata, Toshiya Hiroyoshi, Naohito Isoyama, Koki Fujikawa, Yutaka Miura, Hideyasu Matsuyama, Makoto Kuro-o

CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)

Article Oncology

Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan

Atsushi Ikeda, Takahiro Kojima, Koji Kawai, Shiro Hinotsu, Naoto Keino, Kenichiro Shiga, Hideaki Miyake, Yasuyoshi Miyata, Yutaka Enomoto, Fumitaka Shimizu, Satoshi Anai, Hideyasu Matsuyama, Chieko Suzuki, Yusuke Kanimoto, Keisuke Shigeta, Seiji Naito, Hideyuki Akaza, Hiroyuki Nishiyama

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Immunology

Receptor activator of the NFκB ligand system protects renal function during experimental renal ischemia-reperfusion in mice

Yuki Nakayama, Naohito Isoyama, Takeshi Yamamoto, Yudai Nagata, Masafumi Matsumura, Koki Fujikawa, Hideyasu Matsuyama, Koji Shiraishi

TRANSPLANT IMMUNOLOGY (2020)

Article Medicine, General & Internal

Down-Grading of Ipsilateral Hydronephrosis by Neoadjuvant Chemotherapy Correlates with Favorable Oncological Outcomes in Patients Undergoing Radical Nephroureterectomy for Ureteral Carcinoma

Makito Miyake, Nagaaki Marugami, Yuya Fujiwara, Kazumasa Komura, Teruo Inamoto, Haruhito Azuma, Hiroaki Matsumoto, Hideyasu Matsuyama, Kiyohide Fujimoto

DIAGNOSTICS (2020)

Article Oncology

A new risk stratification model for intravesical recurrence, disease progression, and cancer-specific death in patients with non-muscle invasive bladder cancer: the J-NICE risk tables

Makito Miyake, Hideyasu Matsuyama, Satoshi Teramukai, Fumie Kinoshita, Isao Yokota, Hiroaki Matsumoto, Keiji Shimada, Mitsuru Kinjyo, Tatsuro Shimokama, Koji Okumura, Masaya Yomenori, Hideki Enokida, Masayuki Nakagawa, Yasushi Nakai, Kiyohide Fujimoto

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Oncology

Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma

Yoshiaki Yamamoto, Hideyasu Matsuyama, Hiroaki Matsumoto, Shigeru Sakano, Nakanori Fuji, Kazuo Oba, Mitsutaka Yamamoto, Yoriaki Kamiryo, Takeshi Hiragino, Kazuhiro Nagao, Kimio Takai, Akihiko Aoki

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2020)

Article Oncology

Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance study

Kazuhiro Suzuki, Nobuaki Matsubara, Hirotaka Kazama, Takeshi Seto, Shoko Tsukube, Hideyasu Matsuyama

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2019)

Review Obstetrics & Gynecology

Klinefelter syndrome: From pediatrics to geriatrics

Koji Shiraishi, Hideyasu Matsuyama

REPRODUCTIVE MEDICINE AND BIOLOGY (2019)

No Data Available